Skip to main content
. Author manuscript; available in PMC: 2012 Sep 11.
Published in final edited form as: Clin Genitourin Cancer. 2009 Aug;7(2):E37–E38. doi: 10.3816/CGC.2009.n.020

Figure 1. Changes in Prostate-Specific Antigen With Docetaxel-Based Treatments in the Patient With Metastatic Castration-Resistant Prostate Cancer.

Figure 1

The bars above the curve specify treatment phases, duration of docetaxel treatment, and periods of treatment with bevacizumab (Bev) and thalidomide (Thal). The four arrows denote the important time points in treatment initiation, change, and termination, corresponding to the bars above and the relevant descriptions in the text.

Abbreviation: PSA = prostate-specific antigen